Global EditionASIA 中文双语Français
Home / China / Latest

Potential coronavirus drug approved for marketing

By Zhang Yangfei | | Updated: 2020-02-17 09:43
Share - WeChat

Favipiravir, an antiviral that has shown potential in treating the novel coronavirus, was approved for marketing, the Taizhou government of Zhejiang province announced Sunday.

The drug is approved for marketing in the treatment of influenza, and is one of three drugs demonstrating efficacy against the novel coronavirus in human trials.

The approval document by the National Medical Products Administration said the drug manufacturer, Zhejiang Hisun Pharmaceutical Company, has met requirements to produce the generic form of Favipiravir but needs to continue unfinished research in pharmacy and clinical pharmacology.

The company also received a clinical trial approval by the administration, saying the product is approved for clinical trials on indication for novel coronavirus pneumonia.

Zhang Xinmin, head of the China National Center for Biotechnology Department under the Ministry of Science and Technology, said at a news conference on Saturday that in human trials conducted in Shenzhen, Guangdong province, the drug has shown promising results against the novel coronavirus and mild adverse reactions in patients.

Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349